Middle Meatal Bacteriology During Acute Respiratory Infection in Children
Primary Purpose
Acute Respiratory Infection, Sinusitis
Status
Unknown status
Phase
Phase 4
Locations
Finland
Study Type
Interventional
Intervention
placebo
amoxicillin clavulanate acid
Sponsored by
About this trial
This is an interventional treatment trial for Acute Respiratory Infection focused on measuring respiratory infection, sinusitis, rhinosinusitis, children, middle meatal specimens, respiratory track bacteria, amoxicillin-clavulanate, pneumococci, haemophilus, moraxella
Eligibility Criteria
Inclusion Criteria:
- acute respiratory infection with nasal symptoms (nasal obstruction or discharge)
- seeking medical help from health centre for the respiratory symptoms
- pathogenic bacteria (S pneumoniae, H influenzae or M catarrhalis) identified from right or left nasal middle meatus in the endoscopically taken swab culture sampling taken by a study investigator (all microbiological analyses are done by the National Public Health Institute´s microbiological laboratory in Oulu)
Exclusion Criteria:
- otitis, tonsillitis or other disease requiring antimicrobial treatment
- respiratory infection within 4 weeks of screening
- antimicrobial treatment within 4 weeks of screening
- allergy to penicillin or amoxicillin
Sites / Locations
- Keski-pohjanmaan keskussairaala
- Oulu University Hospital
- Etelä-Pohjanmaan Keskussairaala
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
1
2
Arm Description
placebo Ora-Plus (registered trademark) mixture with an strawberry sweetening agent to make the placebo mixture similar in appearance and taste to active drug
amoxicillin-clavulanate acid
Outcomes
Primary Outcome Measures
Duration of continuous daily symptoms of the acute respiratory infection diagnosed at the study entry.
Secondary Outcome Measures
duration (days)and severity (grade mild, severe) of different symptoms (clear nasal discharge, coloured nasal discharge, nasal obstruction, cough, throat pain, ear ache, fever, headache, diarrhea)
number of days the child is using the following symptomatic drugs (pain killers, nasal vasoconstrictors, nasal corticosteroids, asthma drugs, antihistamines)
number of days the child is not at school and that the parents are not at work
Full Information
NCT ID
NCT00545961
First Posted
October 17, 2007
Last Updated
October 18, 2007
Sponsor
Oulu University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00545961
Brief Title
Middle Meatal Bacteriology During Acute Respiratory Infection in Children
Official Title
Clinical Relevance of Middle Meatal Bacteriology During Acute Respiratory Infection in Children - Randomised, Double-Blinded Clinical Study
Study Type
Interventional
2. Study Status
Record Verification Date
October 2007
Overall Recruitment Status
Unknown status
Study Start Date
November 2007 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2009 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Oulu University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to find out whether the children with respiratory infection and the presence of pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus benefit from antimicrobial treatment.
Detailed Description
Acute sinusitis is one of the most common disease in children requiring antimicrobial treatment. The diagnosis and treatment outcomes of acute sinusitis are contradictory, and better diagnostic criteria are needed. In adults with acute maxillary sinusitis, bacterial culture results obtained from the nasal middle meatus are comparable to those obtained from sinus puncture and aspiration. In children, the presence of pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus during respiratory infection predicts longer duration of signs and symptoms of common cold.
In this randomized placebo-controlled study, the effect of the antimicrobial treatment (amoxicillin-clavulanate) is examined in children with pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus during respiratory infection. The duration of the symptoms and speed of recovery is recognized by daily symptom-diary, the results are compared between the treatment groups.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Respiratory Infection, Sinusitis
Keywords
respiratory infection, sinusitis, rhinosinusitis, children, middle meatal specimens, respiratory track bacteria, amoxicillin-clavulanate, pneumococci, haemophilus, moraxella
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Placebo Comparator
Arm Description
placebo Ora-Plus (registered trademark) mixture with an strawberry sweetening agent to make the placebo mixture similar in appearance and taste to active drug
Arm Title
2
Arm Type
Active Comparator
Arm Description
amoxicillin-clavulanate acid
Intervention Type
Drug
Intervention Name(s)
placebo
Other Intervention Name(s)
Ora-Plus (registered trademark) mixture
Intervention Description
mixture, 0.28125 ml/kg twice a day for 7 days
Intervention Type
Drug
Intervention Name(s)
amoxicillin clavulanate acid
Other Intervention Name(s)
Clavurion mixture (Orion Oy)
Intervention Description
mixture 0.28125 ml / kg twice a day for 7 days
Primary Outcome Measure Information:
Title
Duration of continuous daily symptoms of the acute respiratory infection diagnosed at the study entry.
Time Frame
within the first 3 weeks after enrolment
Secondary Outcome Measure Information:
Title
duration (days)and severity (grade mild, severe) of different symptoms (clear nasal discharge, coloured nasal discharge, nasal obstruction, cough, throat pain, ear ache, fever, headache, diarrhea)
Time Frame
within the first three weeks after enrolment
Title
number of days the child is using the following symptomatic drugs (pain killers, nasal vasoconstrictors, nasal corticosteroids, asthma drugs, antihistamines)
Time Frame
within the first three weeks after the enrolment
Title
number of days the child is not at school and that the parents are not at work
Time Frame
within the first three weeks after enrolment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
13 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
acute respiratory infection with nasal symptoms (nasal obstruction or discharge)
seeking medical help from health centre for the respiratory symptoms
pathogenic bacteria (S pneumoniae, H influenzae or M catarrhalis) identified from right or left nasal middle meatus in the endoscopically taken swab culture sampling taken by a study investigator (all microbiological analyses are done by the National Public Health Institute´s microbiological laboratory in Oulu)
Exclusion Criteria:
otitis, tonsillitis or other disease requiring antimicrobial treatment
respiratory infection within 4 weeks of screening
antimicrobial treatment within 4 weeks of screening
allergy to penicillin or amoxicillin
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Aila A Kristo, MD
Phone
+35883153492
Email
aila.kristo@ppshp.fi
First Name & Middle Initial & Last Name or Official Title & Degree
Olli-Pekka Alho, MD
Phone
+35883153473
Email
olli-pekka.alho@oulu.fi
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jukka-Pekka Kuusiniemi, MD
Organizational Affiliation
Dept of Otolaryngology, Seinäjoki Central Hospital, Finland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eeva Löfgren, MD
Organizational Affiliation
Dept of Otolaryngology, Kokkola Central Hospital, Finland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Anna Marttila, MD
Organizational Affiliation
Dept of Otolaryngology, University of Oulu, Finland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Olli-Pekka Alho, professor
Organizational Affiliation
Dept of Otolaryngology, University of Oulu, Finland
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Aila Kristo, MD
Organizational Affiliation
Dept of Otolaryngology, University of Oulu, Finland
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Ulla Lantto, MD
Organizational Affiliation
Dept of Otolaryngology, University of Oulu, Finland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Keski-pohjanmaan keskussairaala
City
Kokkola
Country
Finland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eeva Löfgren, MD
Facility Name
Oulu University Hospital
City
Oulu
Country
Finland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aila Kristo, MD
First Name & Middle Initial & Last Name & Degree
Anna Marttila, MD
First Name & Middle Initial & Last Name & Degree
Ulla Lantto, MD
Facility Name
Etelä-Pohjanmaan Keskussairaala
City
Seinäjoki
Country
Finland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jukka-Pekka Kuusiniemi, MD
12. IPD Sharing Statement
Learn more about this trial
Middle Meatal Bacteriology During Acute Respiratory Infection in Children
We'll reach out to this number within 24 hrs